【励晶太平洋(00575.HK):江苏万邦医药正在推进SenstendTM于中国国家药监局的新药申请】智通财经APP讯,

智通财经
22 Jul
【励晶太平洋(00575.HK):江苏万邦医药正在推进SenstendTM于中国国家药监局的新药申请】智通财经APP讯,励晶太平洋(00575.HK)发布公告,公司的商业战略合作伙伴江苏万邦生化医药集团有限责任公司(江苏万邦医药,为上海复星医药(集团)股份有限公司的完全控股公司)正在推进SenstendTM于中国国家药品监督管理局(国家药品监督管理局)的新药申请。就此,江苏万邦医药已收到国家药品监督管理局就新药申请档案的第一轮询问,并已及时提交全面回应。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10